Internal Medicine Department, Hospital d'Olot I Comarcal de La Garrotxa, Avinguda Dels Països Catalans 86, 17800, Olot, Girona, Spain.
Tissue Repair and Regeneration Laboratory (TR2Lab), Institut de Recerca I Innovació en Ciències de La Vida I de La Salut a La Catalunya Central (IrisCC), Ctra. de Roda, 70 08500 Vic, Barcelona, Spain.
Curr Heart Fail Rep. 2024 Aug;21(4):1-11. doi: 10.1007/s11897-024-00659-9. Epub 2024 Apr 9.
Diuretics are the cornerstone therapy for acute heart failure (HF) and congestion. Patients chronically exposed to loop diuretics may develop diuretic resistance as a consequence of nephron remodelling, and the combination of diuretics will be necessary to improve diuretic response and achieve decongestion. This review integrates data from recent research and offers a practical approach to current pharmacologic therapies to manage congestion in HF with a focus on combinational therapy.
Until recently, combined diuretic treatment was based on observational studies and expert opinion. Recent evidence from clinical trials has shown that combined diuretic treatment can be started earlier without escalating the doses of loop diuretics with an adequate safety profile. Diuretic combination is a promising strategy for overcoming diuretic resistance in HF. Further studies aiming to get more insights into the pathophysiology of diuretic resistance and large clinical trials confirming the safety and efficacy over standard diuretics regimens are warranted.
利尿剂是急性心力衰竭(HF)和充血的基石治疗方法。由于肾单位重塑,长期使用袢利尿剂的患者可能会产生利尿剂抵抗,需要联合使用利尿剂以改善利尿剂反应并实现充血消退。本综述整合了最近研究的数据,并提供了一种实用的方法来管理 HF 中的充血,重点是联合治疗。
直到最近,联合使用利尿剂的治疗方法还是基于观察性研究和专家意见。最近的临床试验证据表明,联合使用利尿剂可以更早开始,而不会增加袢利尿剂的剂量,且具有足够的安全性。利尿剂联合是克服 HF 中利尿剂抵抗的一种很有前途的策略。需要进一步的研究来深入了解利尿剂抵抗的病理生理学,并进行大型临床试验以确认其相对于标准利尿剂方案的安全性和疗效。